Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
1
1
1
1
1
1
Croissance des revenus (H/H)
0%
0%
0%
0%
0%
0%
Coût des ventes
0
0
0
0
0
0
Bénéfice brut
1
1
1
1
1
1
Vente, Général et Administration
1
1
1
1
1
1
Recherche et développement
0
0
0
0
0
--
Frais d'exploitation
1
1
1
1
1
1
Autres revenus (charges) non opérationnels
0
0
--
--
0
0
Bénéfice avant impôts
0
0
0
0
0
0
Charge d'impôt sur le revenu
0
--
0
0
0
--
Bénéfice net
0
0
0
0
0
-1
Croissance du bénéfice net
--
--
--
--
-100%
0%
Actions en circulation (diluées)
33.37
32.88
32.6
31.7
29.62
26.1
Variation des actions (H-H)
1%
1%
3%
7%
14%
9%
EPS (dilué)
-0.01
-0.01
-0.01
-0.02
-0.02
-0.04
Croissance du EPS
-34%
10%
-48%
-8%
-43%
4%
Flux de trésorerie libre
0
0
0
0
0
0
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
100%
100%
100%
100%
100%
100%
Marge opérationnelle
0%
0%
0%
0%
0%
0%
Marge bénéficiaire
0%
0%
0%
0%
0%
-100%
Marge du flux de trésorerie libre
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
0
Marge EBITDA
0%
0%
0%
0%
0%
0%
D&A pour le résultat opérationnel
0
0
0
0
0
0
EBIT
0
0
0
0
0
0
Marge EBIT
0%
0%
0%
0%
0%
0%
Taux d'imposition effectif
0%
--
0%
0%
0%
--
Follow-Up Questions
Quels sont les états financiers clés de Vycor Medical Inc ?
Quels sont les ratios financiers clés pour VYCO ?
Comment les revenus de Vycor Medical Inc sont-ils répartis par segment ou géographie ?
Vycor Medical Inc est-elle rentable ?
Vycor Medical Inc a-t-elle des passifs ?
Combien d'actions en circulation Vycor Medical Inc a-t-elle ?
Statistiques clés
Clôture préc.
$0.11
Prix d'ouverture
$0.11
Plage de la journée
$0.11 - $0.11
Plage de 52 semaines
$0.051 - $0.5
Volume
1.0K
Volume moyen
11.5K
BPA (TTM)
-0.00
Rendement en dividend
--
Capitalisation boursière
$3.6M
Qu’est-ce que VYCO ?
Vycor Medical, Inc. engages in the provision of innovative surgical and therapeutic solutions to the medical community. The company is headquartered in Boca Raton, Florida and currently employs 7 full-time employees. The company went IPO on 2009-03-31. The firm designs, develops and markets neurological medical devices and therapies. The firm operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage, such as that caused by a stroke. Vycor Medical’s ViewSite Brain Access System (VBAS) is a next-generation retraction and access system. VBAS is a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system is used in over 300 hospitals in the United States and in numerous countries internationally. NovaVision products include Visual Restoration Therapy (VRT) and NeuroEyeCoach.